Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

13.29 +0.29 (+2.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,536,353
Open 12.94
Bid (Size) 13.35 (50)
Ask (Size) 13.74 (1)
Prev. Close 13.00
Today's Range 12.80 - 14.98
52wk Range 3.730 - 19.18
Shares Outstanding 48,743,140
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly. 
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
Via Benzinga

Performance

YTD
-26.4%
-26.4%
1 Month
-3.0%
-3.0%
3 Month
-10.9%
-10.9%
6 Month
+101.4%
+101.4%
1 Year
+175.7%
+175.7%

More News

Read More
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Via Chartmill
Which stocks are moving on Thursday?
Via Chartmill
uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic
Via Stocktwits
Topics Bankruptcy
Exposures Financial Legal Product Safety
There are notable gap-ups and gap-downs in today's session.
Via Chartmill
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday
Via Benzinga
What's going on in today's pre-market session
Via Chartmill
Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?
Via Benzinga
Exposures Product Safety
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
Via Benzinga
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Pricing of its Public Offering
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Proposed Public Offering
From uniQure Inc.
Via GlobeNewswire
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?
Via The Motley Fool
S&P 500 Edges Lower; AutoZone Posts Downbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings
Via Benzinga
United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Dow Falls 150 Points; Oracle Posts Downbeat Results
Via Benzinga
Topics Stocks
Exposures US Equities
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug
Via Investor's Business Daily
Exposures Product Safety
Why Is uniQure Stock Skyrocketing On Tuesday?
Via Benzinga
Exposures Product Safety
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
From uniQure Inc.
Via GlobeNewswire

Frequently Asked Questions

Is uniQure N.V. - Ordinary Shares publicly traded?
Yes, uniQure N.V. - Ordinary Shares is publicly traded.
What exchange does uniQure N.V. - Ordinary Shares trade on?
uniQure N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for uniQure N.V. - Ordinary Shares?
The ticker symbol for uniQure N.V. - Ordinary Shares is QURE on the Nasdaq Stock Market
What is the current price of uniQure N.V. - Ordinary Shares?
The current price of uniQure N.V. - Ordinary Shares is 13.29
When was uniQure N.V. - Ordinary Shares last traded?
The last trade of uniQure N.V. - Ordinary Shares was at 04/21/25 04:00 PM ET
What is the market capitalization of uniQure N.V. - Ordinary Shares?
The market capitalization of uniQure N.V. - Ordinary Shares is 647.80M
How many shares of uniQure N.V. - Ordinary Shares are outstanding?
uniQure N.V. - Ordinary Shares has 648M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.